British pharmaceuticals group AstraZeneca has approached US rival Gilead Sciences over a possible record merger, Bloomberg reported, as the pair spearhead treatments for COVID-19.
AstraZeneca informally contacted Gilead last month, Sunday’s report said, adding that a combined group would be worth a record-breaking $236 billion when taking into account the companies’ closing valuations Friday.
That was trimmed Monday, with AstraZeneca’s share price down 2.14 percent at the start of London trading.
Gilead’s antiviral drug remdesivir has been shown to help severely ill coronavirus patients, while AstraZeneca is trialing a COVID-19 vaccine.
Gilead shares surge on report of drug’s success on COVID-19
© 2020 AFP
Astra eyes record merger with drug rival Gilead: report (2020, June 8)
retrieved 8 June 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022